BioTech Medics, Inc. Added to the StockProfile.com Roster
Published: May 04, 2010
DALLAS, TX--(Marketwire - May 04, 2010) -
StockProfile.com provides the investing public with a free unique information portal for investors who like to conduct their own research and make their own investment decisions. The platform allows users to review and investigate dynamic publicly traded companies in a user-friendly environment.
BioTech Medics, Inc. was chosen by StockProfile.com to provide independent minded investors seeking new growth and undervalued company information about BMCS for investment. The profile is listed at www.StockProfile.com and can be viewed by searching under the stock symbol: BMCS.
"In our continuing effort to increase shareholder value and to increase public awareness of our growing and dynamic company we are pleased to have been scrutinized and accepted by StockProfile.com," said Keith Houser, BioTech's CEO. "We are delighted to be added to the select StockProfile.com roster of exciting growth companies. BioTech was not required to compensate Stock Profile for BioTech's listing."
About Bio Tech Medics:
BioTech Medics is a 21st Century Alternative Medicine company. BioTech owns, operates or affiliates with BioTech Pain Management Laser Centers in Dallas, TX; Santa Fe and Albuquerque, NM; and Newport Beach, CA. BioTech's lasers have FDA 510(k) authorizations. Over 94 pain ailments can be treated without drugs or surgery with the deep penetrating high powered therapeutic lasers including back pain, carpal tunnel, arthritis and nerve pain. Biotech has a 90% success rate in reducing or eliminating pain.
BioTech also owns 4 US Granted Letters of Patent on its proprietary SHBAN™ Alcohol Free Hand Sanitizer. SHBAN has been tested over 15 years and was developed by a former scientist of Merck & Co. SHBAN is a green product made in Texas. SHBAN is long lasting and has been independently tested and proven to kill the H1N1 (Swine) Influenza A, the H5N1 (Avian Bird) Influenza A, MRSA's, Staph and over 20 other germs and fungus.
Safe Harbor: Forward-Looking Statements
This release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). The FDA has not evaluated the SHBAN statements above. SHBAN is not intended to diagnose, treat or cure any disease
USA Sr. V.P. Sales